Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 150

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 150
---
 analysis, evaluation, monitoring and exercise of general oversight of all proceedings and activities related to any strategic transaction proposal. The Strategic Transaction Committee was not delegated the authority to approve any particular
transaction, but was directed to provide recommendations to Aadi’s board of directors with respect to various proposals and/or strategic partners. From March 22, 2024 through August 26, 2024, the Strategic Transaction Committee held
nine meetings with Aadi’s management team and its advisers to discuss, among other things, potential strategic opportunities, the asset screening process, due diligence considerations, and the retention of potential investment banks and
business development partners to assist in business development efforts.

On May 11, 2024, following authorization from Aadi’s board of
directors and based upon a recommendation from the Strategic Transaction Committee after a review of various alternatives, Aadi signed an engagement letter with Leerink Partners to serve as its financial advisor in connection with Aadi’s
comprehensive assessment of strategic options, including those related to acquisition or in-licensing opportunities.

On June 13, 2024, Aadi engaged a business development consultant with expertise in ADC and bi-specific programs
under development in China. The consultant introduced Aadi to the ADC portfolio of WuXi Biologics. In order to discuss and evaluate a possible transaction, Aadi entered into a confidentiality agreement with WuXi

- 98 -

Biologics on June 19, 2024. Aadi’s initial focus was on the Seizure Related 6 Homolog (SEZ6) ADC asset, followed by later interest in the Protein Tyrosine Kinase 7 (PTK7) CPT113 ADC and
Mucin-16 (MUC16) ADC assets amongst other programs. Following an introductory videoconference meeting between representatives of Aadi and WuXi Biologics on June 20, 2024, Aadi entered into a three-way mutual confidentiality agreement with WuXi Biologics and Hangzhou DAC, a developer of linker-payload technology used in WuXi Biologics’ ADC portfolio, on July 2, 2024.

On July 9, 2024, the Strategic Transaction Committee held a meeting to discuss strategic opportunities with Aadi’s management team. At the meeting,
the committee deliberated with Aadi’s management team regarding a refined strategy for evaluating ADC opportunities, including establishing criteria for validated targets, limited competition, next wave linker-payload platforms, and the ability
of the drug program to go